Bacillus Subtilis Expressing Epidermal Growth Factors Induces Intestinal Repair and Growth-Promoting in Mice

Xiaoying Wu,Yue Li,Xiue Jin,Deshi Shi,xiliang Wang

DOI: https://doi.org/10.21203/rs.3.rs-495723/v1

2021-01-01

Abstract:Abstract Background: Probiotics are widely acknowledged for their pro-health attributes, but the efficacy of traditional probiotics is quite limited. This limitation can be overcome using a gene engineered to enhance the efficacy of existing probiotics. In this study, a strain of Bacillus subtilis (WB800) expressing the eukaryotic protein porcine epidermal growth factor (pEGF) was generated via genetic modification, and mice with intestinal injury were used as a model to evaluate the potential of this bioengineered probiotic in preventing or treating intestinal damage. Integration of the pEGF gene into the B. subtilis WB800 genome using an integrated expression vector pDG1730 resulted in stable expression of pEGF in B. subtilis (dubbed WB-EGF). Results: Female the Institute for Cancer Research (ICR) mice with intestinal damage received recombinant WB-EGF (1×108 –8×108 CFU/mL) for 10 d before collection of blood and intestinal tissues. Mice receiving WB-EGF had significantly higher body weight and longer intestinal villi than those of mice treated with Luria-Bertani (LB) broth or B. subtilis transformed with an empty vector. Cell proliferation assays confirmed enhanced intestinal cell proliferation in mice receiving WB-EGF. Conclusions: This study provides evidence that WB-EGF may have use as a novel therapy for early prevention or treatment of intestinal damage and for promoting intestinal development. The recombinant B. subtilis strain developed here can expected to provide protection when used as a feed additive in animals with gastrointestinal infections.